Inclusion Criteria:  Patient completed Study NCNP/DMT02  Exclusion Criteria:  Patient had any serious adverse events in Study NCNP/DMT02 that, in the opinion of the Investigator and/or Sponsor, was probably or definitely related to NS-089/NCNP-02 use and precludes safe use of NS-089/NCNP-02 for the patient in this study. Patient had a treatment which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NCNP/DMT02. Patient took any other investigational drugs after completion of Study NCNP/DMT02. Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.